26.08
1.13 (4.53%)
| Previous Close | 24.95 |
| Open | 24.70 |
| Volume | 611,525 |
| Avg. Volume (3M) | 1,244,193 |
| Market Cap | 1,987,955,712 |
| Price / Sales | 3.51 |
| Price / Book | 3.05 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 |
| Operating Margin (TTM) | -81,161.54% |
| Diluted EPS (TTM) | -1.50 |
| Quarterly Revenue Growth (YOY) | -90.20% |
| Total Debt/Equity (MRQ) | 0.15% |
| Current Ratio (MRQ) | 30.97 |
| Operating Cash Flow (TTM) | -81.98 M |
| Levered Free Cash Flow (TTM) | -57.18 M |
| Return on Assets (TTM) | -12.85% |
| Return on Equity (TTM) | -16.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | CG Oncology, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.63 |
|
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.17% |
| % Held by Institutions | 105.34% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 56.00 (Morgan Stanley, 114.72%) | Buy |
| Median | 55.00 (110.89%) | |
| Low | 53.00 (RBC Capital, 103.22%) | Buy |
| Average | 54.67 (109.62%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 25.96 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 19 Aug 2025 | 55.00 (110.89%) | Buy | 25.56 |
| RBC Capital | 16 Jul 2025 | 53.00 (103.22%) | Buy | 26.08 |
| Morgan Stanley | 17 Jun 2025 | 56.00 (114.72%) | Buy | 26.24 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 Aug 2025 | Announcement | CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences |
| 08 Aug 2025 | Announcement | CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates |
| 29 Jul 2025 | Announcement | Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals |
| 07 Jul 2025 | Announcement | Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs |
| 05 Jun 2025 | Announcement | CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |